logo-loader
Genprex, Inc.

Genprex updates on positive results for its lung cancer drug Oncoprex

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner updates Proactive Investors on the latest developments with the Texas-based company's non-small cell lung cancer drug, including positive study results done in humanized mice.

Varner says the study of its lead drug Oncoprex at The University of Texas MD Anderson Cancer Center was completed in April after examining the effects of the tumor suppressor gene TUSC2 found in Oncoprex in combination with immunotherapy treatment.

Quick facts: Genprex, Inc.

Price: $0.94

Market: NASDAQ
Market Cap: $14.89 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Genprex Inc making progress on branding for its lead cancer therapy, Oncoprex

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the biotech has initiated the first phase of branding for its lead drug candidate, Oncoprex, an immunogene therapy to treat non-small cell lung cancer. Varner says the Texas-based company has completed the creation and submission of...

on 08/06/2019

2 min read